Please login to the form below

Not currently logged in
Email:
Password:

FDA warning letter for Aurobindo

India based generics manufacturer, Aurobindo Pharma, has received warning letters from the US Food and Drug Administration calling for changes at two of the company's facilities

India based generics manufacturer, Aurobindo Pharma, has received warning letters from the US Food and Drug Administration (FDA) calling for changes at two of the company's facilities.

In a statement, the company explained that the FDA has requested a 'detailed action plan' for improvements regarding packaging and labelling compliance at unit three of its Hyderabad plant. This was based on a previous field alert report by the agency.

Aurobindo have 15 working days to submit the action plan, with the opportunity to discuss the situation at a regulatory meeting with the FDA.

Aurobindo said it was in the process of responding to these requests.

The FDA also issued an official warning letter following an earlier import alert on Aurobindo's unit six cephalosporin manufacturing plant, which required detention of products from the facility.

23rd May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics